Mersana Therapeutics Provides Statement About SVB

CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided an update about its capital resources. A de minimis amount of Mersana’s capital is currently held in a checking account at Silicon Valley Bank (SVB). The balance of the company’s capital resources is held in a custodial account managed by another institution and in money market funds of institutions other than SVB.

Mersana has a loan and security agreement with Oxford Finance LLC and SVB. As previously disclosed, to date the company has borrowed $25 million under the loan agreement, and $15 million is available to be borrowed at the company’s option under the terms of the loan agreement. The recent closure of SVB and the appointment of the Federal Deposit Insurance Corporation as receiver is not a repayment trigger pursuant to the terms of the loan agreement.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE-A, a Phase 1 clinical trial evaluating UpRi in combination with carboplatin; and UP-NEXT, a Phase 3 clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Mersana is also advancing XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in Phase 1 trials. In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines. Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.

Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com

Staff

Recent Posts

Optimind Pharma Closes First Tranche of Private Placement

Toronto, Ontario--(Newsfile Corp. - July 8, 2024) - Optimind Pharma Corp. (CSE: OMND) ("Optimind" or…

12 mins ago

Element Science Receives Prestigious International Red Dot Design Award for Innovative Jewel® Patch Wearable Cardioverter Defibrillator

Novel technology recognized for its groundbreaking design and patient-centric innovationSAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative…

2 hours ago

StoryCorps Launches One Small Step America, a National Effort to Bridge Divides During a Contentious Election Year

One Small Step Pairs Strangers With Opposing Political Beliefs for One-on-One Conversations, Not to Debate…

5 hours ago

Navigate Announces Acquisition of Health Solutions, LLC

Positioning Navigate as a Leader in Comprehensive Wellbeing Solutions WEST DES MOINES, Iowa, July 8,…

5 hours ago

FDA Updates Guidance to Further Empower Companies to Address the Spread of Misinformation

SILVER SPRING, Md., July 8, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration…

5 hours ago

Goodix Launches Its Latest Automotive-Grade Bluetooth LE SoC and CGM Solutions at electronica China 2024

SHENZHEN, China, July 8, 2024 /PRNewswire/ -- Goodix Technology today unveiled its Continuous Glucose Monitoring…

5 hours ago